

Generating evidence for HTA using the OMOP common data model and standardised analytical tools

Seamus Kent (seamus.kent@nice.org.uk)

Scientific Adviser, NICE

Background

- NICE is the HTA body for England
 - Make reimbursement decisions for new medical technologies
 - Issue clinical guidelines
- NICE are a partner in EHDEN
- Aims within EHDEN
 - Understand the usefulness of the common data model, standardised analytical tools, and the federated data network for HTA in Europe
 - Inform the further development of OMOP and tools

NICE

- Evidence generation for regulatory and HTA decision-making

What is HTA?

- Systematic evaluation of properties and effects of health technologies to inform medical decision making
- Follows regulatory authorisation and can be used to make reimbursement and/or pricing decisions
- Can include
 - Relative effectiveness assessment
 - Cost-effectiveness assessment
 - Budget impact analysis
 - Decision modelling

The role of RWE

➤ Comparative effectiveness

- Main evidence or supplement, managed access, reviews

➤ Other uses

- Characterise target population, treatment pathways and utilisation, and outcomes
- Model epidemiological data (e.g. incidence, death rate)
- Extrapolation of overall and progression free survival
- Model healthcare utilisation and cost, HRQL
- Understand relationship between surrogate and final clinical endpoints
- Validation

What is the value of OMOP to HTA?

- Data identification & access
- Multidatabase studies
 - Increase precision, explore heterogeneity, validate findings, translate results to other populations or settings
- Timely and robust evidence generation
- Transparency
 - Use of open-source standardised tools
 - Impose good research practices
 - Tools for quality assessment

Healthcare utilisation in COPD

➤ Aims

- Estimate annual primary care healthcare visits for patients with COPD by disease severity
- Model outcomes by staff role (GP, nurse practitioner, other) and visit type (clinic, home, telephone)

➤ Data

- CPRD (UK; via University of Oxford)
- IPCI (NL; via Erasmus MC)

Healthcare utilisation in COPD, challenges

- Representation of healthcare visits in OMOP
- Mapping of utilisation data
- Analytical tools

Representation of healthcare visits in OMOP

- Relevant tables
 - Visit occurrence
 - Provider specialty
 - Care site

- Vocabularies
 - Visit (OMOP)
 - Provider (OMOP)
 - Others, e.g. HES specialty, NUCC, Medicare specialty, UB04, ...

Mapping of utilisation data, CPRD

- Source data
 - 'consultation' table contains all interactions with primary care including admin tasks, i.e. not just GP visits
 - ~70 staff roles and visit types
- Mapping (Janssen / Oxford)
 - No pre-cleaning
 - Visit occurrence: all interactions mapped to 'Outpatient visit' (9202)
 - Provider specialty: mapped to 25 standard concepts across 4 vocabularies; 'Unknown Physician Specialty' used for diverse providers including GPs and administrative functions
 - Care site: no mapping; all contacts recorded as 'Public Health Clinic'

Mapping of utilisation data, IPCI

➤ Mapping (EMC)

- Pre-cleaning, retain GP visits
- Visit occurrence: all interactions mapped to 'Outpatient visit' (9202)
- Provider specialty: no mapping
- Care site: no mapping; all contacts recorded as '?'

Analytical tools

- Modelling annual healthcare utilisation and cost data
 - Continuous outcomes (or counts)
 - Highly skewed, excess zeros
 - Panel data
 - GLM, two-part models / zero-inflated models
 - Model outcomes as a function of GOLD stage and other covariates (e.g. age, sex, exacerbations, MI, BMI, smoking)

- What kind of question is this?
 - Characterisation? PLE? PLP?

- Developing tools for model estimation & exploration

Recommendations

- Ensure HTA or health service research expertise in mapping data to the OMOP common data model
- Consider extensions to vocabularies to reflect main categories of healthcare visit
- Standardised recording of type of visit
- Develop tools and dashboards for HTA
 - Continuous outcome models
 - Extrapolation